울혈성 심부전(CHF) 치료제 시장 : 제품별, 최종 용도별, 예측(2024-2032년)

Global Congestive Heart Failure (CHF) Treatment Devices Market size will grow at a 6.4% CAGR between 2024 and 2032, owing to the rising usage of pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices coupled with continuous regulatory approvals of new technologies. Rising innovations in CHF treatment devices are offering improved effectiveness and patient outcomes for meeting the evolving patient needs. The introduction of novel devices is also enhancing the treatment options, leading to increased product adoption and market expansion.

For instance, in December 2022, Abbott introduced Navitor, its latest transcatheter aortic valve implantation (TAVI) system, in India, for offering a minimally invasive solution for severe aortic stenosis patients at high surgical risk. This launch extends advanced treatment options to a broader population for addressing heart valve diseases more effectively.

The CHF treatment devices industry is fragmented on the basis of product, end-use, and region.

Based on product, the market value from the pacemaker segment will witness 4.5% CAGR up to 2032, attributed to the widespread use in managing CHF-related arrhythmias and heart rhythm disorders. Pacemakers play a crucial role in regulating heart rhythms and improving cardiac function in CHF patients. With advancements in pacemaker technology, such as remote monitoring and programmability, the adoption of pacemakers will further grow due to their effectiveness and versatility in managing CHF symptoms.

Congestive heart failure treatment devices industry size from the cardiac clinic segment will garner 6.5% gains from 2024 to 2032. This is propelled by the increasing number of specialized cardiac clinics focusing on CHF management. Cardiac clinics often adopt a multidisciplinary approach, utilizing a range of devices such as pacemakers, implantable cardioverter-defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices. The growing emphasis on specialized care and innovative treatments will add to the segment growth.

Asia Pacific will secure an 8.3% CAGR in the CHF treatment devices market during 2024 and 2032, driven by the increasing prevalence of cardiovascular diseases, rising geriatric population, and improving healthcare infrastructure. Countries like China, Japan, and India are significantly contributing to a high burden of CHF cases. Moreover, the growing adoption of advanced treatment devices and government initiatives to improve cardiac care will further strengthen the market development in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & working
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of heart failure and cardiovascular diseases
    • 3.2.1.2 Technological advancements and introduction of innovative devices
    • 3.2.1.3 Favorable reimbursement scenario
    • 3.2.1.4 Increasing awareness regarding heart failure treatment
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of devices
    • 3.2.2.2 Product recalls
• 3.3 Growth potential analysis
• 3.4 Porter's analysis
  • 3.4.1 Supplier power
  • 3.4.2 Buyer power
  • 3.4.3 Threat of new entrants
  • 3.4.4 Threat of substitutes
  • 3.4.5 Industry rivalry
• 3.5 PESTEL analysis
• 3.6 Pricing analysis, 2023
• 3.7 Number of heart failures at global and regional, 2023
• 3.8 Reimbursement scenario
• 3.9 Regulatory landscape
• 3.10 Technological landscape
• 3.11 Pipeline products
• 3.12 Future market trends
• 3.13 Gap analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Defibrillators
  • 5.2.1 Implantable cardioverter defibrillators (ICDs)
    • 5.2.1.1 Transvenous ICD
      • 5.2.1.1.1 Single-chamber ICDs
      • 5.2.1.1.2 Dual-chamber ICDs
    • 5.2.1.2 Subcutaneous ICD
  • 5.2.2 External cardioverter defibrillator
    • 5.2.2.1 Manual external defibrillator
    • 5.2.2.2 Automated external defibrillator
      • 5.2.2.2.1 Semi-automated external defibrillator
      • 5.2.2.2.2 Fully automated external defibrillator
    • 5.2.2.3 Wearable external cardioverter defibrillator
• 5.3 Pacemakers
  • 5.3.1 Implantable pacemakers
  • 5.3.2 External pacemakers
• 5.4 Cardiac resynchronization therapy devices
  • 5.4.1 Cardiac resynchronization therapy-defibrillators (CRT-D)
    • 5.4.1.1 MRI compatible CRT-D devices
    • 5.4.1.2 Conventional CRT-D devices
  • 5.4.2 Cardiac resynchronization therapy-pacemakers (CRT-P)
    • 5.4.2.1 MRI Compatible CRT-P devices
    • 5.4.2.2 Conventional CRT-P devices
• 5.5 Ventricular assist devices (VADs)
  • 5.5.1 Left ventricular assist devices (LVADs)
  • 5.5.2 Right ventricular assist devices (RVADs)
  • 5.5.3 Biventricular assist devices (BIVADs)
  • 5.5.4 Percutaneous ventricular assist devices (PVADs)
  • 5.5.5 Total artificial heart
• 5.6 Other products

Chapter 6 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospitals
• 6.3 Cardiac clinics
• 6.4 Ambulatory surgical centers
• 6.5 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 South Africa
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Abbott Laboratories
• 8.2 Biotronik SE & Co. KG
• 8.3 Boston Scientific Corporation
• 8.4 Koninkilijke Philips N.V.
• 8.5 Lepu Medical Technology Co. Ltd.
• 8.6 LivaNova PLC
• 8.7 MEDICO S.p.A.
• 8.8 Medtronic plc
• 8.9 MicroPort Scientific Corporation
• 8.10 OSCOR Inc.
• 8.11 Schiller AG
• 8.12 Shree Pacetronix Ltd.
• 8.13 St. Jude Medical, Inc.
• 8.14 Stryker Corporation
• 8.15 Terumo Corporation